Welcome to our dedicated page for Rockwell Med news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Med stock.
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. The Rockwell Medical (RMTI) news feed on Stock Titan focuses on company announcements that relate to its hemodialysis concentrates portfolio, supply agreements with dialysis providers, operational updates, and financial results.
Investors and healthcare observers following RMTI news can expect coverage of product purchase agreements with large dialysis providers, health systems, and specialized care organizations. Recent company communications describe multi-year contracts that include utilization or purchase minimums, options to renew, and supply of liquid and dry acid and bicarbonate concentrates, as well as Rockwell Medical’s dry acid concentrate mix system and bicarbonate cartridge. News items also highlight the company’s efforts to expand its customer base, including adding new dialysis customers in different regions of the United States.
The RMTI news stream also includes quarterly financial and operational results, typically released through earnings press releases and accompanied by conference call details. These updates discuss net sales, gross margin, adjusted EBITDA, and cash position, along with commentary on customer transitions, contract renewals, and manufacturing efficiency. In addition, Rockwell Medical issues news on leadership changes, such as board appointments and executive promotions, and on operational roles related to manufacturing and supply chain management.
Further topics in Rockwell Medical news include participation in industry events, such as exhibiting its hemodialysis concentrates portfolio at professional nephrology conferences, and recognition as a Great Place to Work® and a Fortune Best Workplaces in Manufacturing & Production™ honoree. For users tracking RMTI, this news page provides a centralized view of the company’s corporate developments, financial disclosures, and updates on its hemodialysis products and customer relationships.
Rockwell Medical reported its 2020 financial results, achieving revenues of $62.2 million, with a cash balance of $58.7 million at year-end. The company highlighted growth in its dialysis business, particularly through Triferic, which generated approximately $1.1 million in revenue. Cost savings of $296,000 were noted from Triferic's use in clinics. The company is focusing on expanding its FPC technology for treating iron deficiency anemia and acute heart failure. They appointed several industry leaders to their board to strengthen management.
Rockwell Medical, Inc. (Nasdaq: RMTI) will host a conference call on March 31, 2021, at 4:30 p.m. ET to discuss its financial results for the year ended December 31, 2020, along with operational highlights. Interested parties can join by calling (877) 383-7438 or (678) 894-3975, and a live webcast will be available on their investor website. The company focuses on treating iron deficiency and anemia management, particularly in hemodialysis patients. Its FDA-approved therapies, Triferic Dialysate and Triferic AVNU, aim to improve outcomes for this patient demographic.
Rockwell Medical (Nasdaq: RMTI) announced that its executive team will present at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 1:30 p.m. Eastern Time. The pre-recorded presentation will be accessible in the ‘Investors’ section of the Company’s website. Rockwell Medical focuses on transforming iron deficiency and anemia management, particularly in end-stage kidney disease, with FDA-approved treatments Triferic and Triferic AVNU, which uniquely maintain hemoglobin levels in hemodialysis patients.
Rockwell Medical (Nasdaq: RMTI) announced the availability of Triferic AVNU, an FDA-approved IV formulation for iron replacement in hemodialysis patients with chronic kidney disease. Approved in March 2020, Triferic AVNU enhances treatment options for patients by allowing greater flexibility in iron maintenance therapy. This product is distributed via Rockwell Medical and Metro Medical, targeting U.S. dialysis clinics. Triferic and Triferic AVNU are the only approved therapies in the U.S. for maintaining hemoglobin in hemodialysis patients, addressing significant medical needs.
Rockwell Medical (Nasdaq: RMTI) announced that its partner, Jeil Pharmaceutical, submitted New Drug Applications for Triferic AVNU and Triferic Dialysate in South Korea, targeting over 82,000 hemodialysis patients. This milestone is significant for both the company and patients with hemodialysis-dependent chronic kidney disease. Rockwell Medical has an exclusive license agreement with Jeil for Triferic in South Korea, entitling it to milestone payments and royalties on sales.
Rockwell Medical (Nasdaq: RMTI) announced the enrollment of the first patient in a pivotal Phase 3 trial for Triferic Dialysate in China, a significant step towards regulatory approval. With over 600,000 patients receiving hemodialysis in China, this market represents a key opportunity. The trial aims to confirm the efficacy and safety of Triferic in maintaining iron levels for anemic patients with chronic kidney disease. Rockwell's partnership with Wanbang Biopharmaceuticals facilitates commercialization efforts, enhancing the availability of Triferic in this growing market.
Rockwell Medical (Nasdaq: RMTI) announced that its executive management team will present at the H.C. Wainwright BioConnect 2021 Conference. The presentation will be available to the public on January 11, 2021, at 6:00 a.m. ET, and will be archived for 30 days on the company's website. Rockwell Medical focuses on transforming iron deficiency treatment, particularly for end-stage kidney disease patients, through its FDA-approved therapies, Triferic Dialysate and Triferic AVNU. These therapies are designed to replace iron and maintain hemoglobin without increasing iron stores.
Rockwell Medical (RMTI) has appointed Andrea Heslin Smiley, an experienced life sciences executive, to its Board of Directors as of December 11, 2020. With nearly 30 years in the biopharmaceutical field, Ms. Smiley brings a strong background in patient adherence and product commercialization. Her expertise is expected to enhance the value of Rockwell's Triferic® therapies and support its expansion into the home infusion market. This leadership change aims to bolster the company’s strategic direction and reinforces its commitment to advancing iron deficiency treatments.
Rockwell Medical reported Q3 2020 financial results, achieving revenue of $15.3 million, a slight decline of 0.8% from the previous year. The company ended the quarter with $67.3 million in cash and equivalents, bolstered by a $35 million registered direct offering. Rockwell plans to launch Triferic® AVNU in Q1 2021 and enroll the first patient for its Phase 3 trial in China. Additionally, they aim to expand the FPC platform for new indications. The net loss for the quarter was $7.4 million, marking an improvement over last year's loss.
Rockwell Medical, a biopharmaceutical company, will host a conference call on November 9, 2020, at 4:30 p.m. ET, to discuss its financial results for Q3 2020 and recent operational developments. Interested participants can join by dialing (877) 383-7438 for local access or (678) 894-3975 for international access, with a conference ID of 7679074. The call will also be available via live webcast. Rockwell Medical specializes in iron deficiency treatments for patients with end-stage kidney disease through its FDA-approved products, Triferic Dialysate and Triferic AVNU.